Pan-Cancer Study of SHC-Adaptor Protein 1 (SHC1) as a Diagnostic, Prognostic and Immunological Biomarker in Human Cancer
Background: Recent studies highlight the carcinogenesis role of SHC-adaptor protein 1 (SHC1) in cancer initiation, development, and progression. However, its aberrant expression, diagnostic and prognostic value remain unknown in a variety of tumors.Methods: The SHC1 expression profiles were analyzed...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2022.817118/full |
| _version_ | 1818274292744323072 |
|---|---|
| author | Jianlin Chen Gan Gao Limin Li Junping Ding Xianhua Chen Jianfei Lei Haihua Long Lihua Wu Xin Long Lian He Yongqi Shen Jinzhong Yang Yonggang Lu Yifan Sun |
| author_facet | Jianlin Chen Gan Gao Limin Li Junping Ding Xianhua Chen Jianfei Lei Haihua Long Lihua Wu Xin Long Lian He Yongqi Shen Jinzhong Yang Yonggang Lu Yifan Sun |
| author_sort | Jianlin Chen |
| collection | DOAJ |
| description | Background: Recent studies highlight the carcinogenesis role of SHC-adaptor protein 1 (SHC1) in cancer initiation, development, and progression. However, its aberrant expression, diagnostic and prognostic value remain unknown in a variety of tumors.Methods: The SHC1 expression profiles were analyzed using GTEx database, TCGA database, Oncomine and CPTAC database. The survival analysis was conducted using GEPIA2, Kaplan-Meier Plotter, UALCAN, and PrognoScan. The diagnostic values of SHC1 were calculated with the “pROC” package in R software. The genetic alteration of SHC1 and mutations were analyzed using cBioPortal. TIMER2 was employed to estimate the correlations between SHC1 expression and tumor-infiltrating immune cells in the TCGA cohort. Enrichment analysis of SHC1 was conducted using the R package “clusterProfiler.”Results: SHC1 was ubiquitously highly expressed and closely associated with worse prognosis of multiple major cancer types (all p < 0.05). Further, SHC1 gene mutations were strongly linked to poor OS and DFS in SKCM (all p < 0.05). An enhanced phosphorylation level of SHC1 at the S139 site was observed in clear cell RCC. Additionally, the results revealed SHC1 expression was strongly linked to TMB, MMRs, MSI, TAMs, DNA methylation, m6A RNA methylation, tumor-associated immune infiltration, and immune checkpoints in multiple cancers (all p < 0.05). In addition, the results of the ROC analysis indicated the SHC1 exhibited strong diagnostic capability for KICH (AUC = 0.92), LIHC (AUC = 0.95), and PAAD (AUC = 0.95). Finally, enrichment analysis indicated that SHC1 may potentially involve in the regulation of numerous signaling pathways in cancer metabolism and protein phosphorylation-related functions.Conclusions: These findings highlight that SHC1 plays an important role in the tumor immune microenvironment, and SHC1 has been identified to have prognostic and diagnostic value in multiple cancers. Thus, SHC1 is a potential target for cancer immunotherapy and effective prognostic and diagnostic biomarker. |
| first_indexed | 2024-12-12T22:11:33Z |
| format | Article |
| id | doaj.art-1a0305fc87fa487ea2869406670134ec |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-12-12T22:11:33Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-1a0305fc87fa487ea2869406670134ec2022-12-22T00:10:13ZengFrontiers Media S.A.Frontiers in Genetics1664-80212022-05-011310.3389/fgene.2022.817118817118Pan-Cancer Study of SHC-Adaptor Protein 1 (SHC1) as a Diagnostic, Prognostic and Immunological Biomarker in Human CancerJianlin Chen0Gan Gao1Limin Li2Junping Ding3Xianhua Chen4Jianfei Lei5Haihua Long6Lihua Wu7Xin Long8Lian He9Yongqi Shen10Jinzhong Yang11Yonggang Lu12Yifan Sun13Departments of Clinical Laboratory, Key Laboratory of medical molecular diagnostics of Liuzhou, Key Laboratory for nucleic acid molecular diagnosis and application of Guangxi health and wellness Commission, Affiliated Liutie Central Hospital of Guangxi Medical University, Liuzhou, ChinaDepartments of Clinical Laboratory of Liuzhou Maternity and Child Healthcare Hospital, Liuzhou, ChinaDepartments of Clinical Laboratory of Liuzhou People's Hospital, Liuzhou, ChinaDepartments of Clinical Laboratory, Key Laboratory of medical molecular diagnostics of Liuzhou, Key Laboratory for nucleic acid molecular diagnosis and application of Guangxi health and wellness Commission, Affiliated Liutie Central Hospital of Guangxi Medical University, Liuzhou, ChinaDepartments of Clinical Laboratory, Key Laboratory of medical molecular diagnostics of Liuzhou, Key Laboratory for nucleic acid molecular diagnosis and application of Guangxi health and wellness Commission, Affiliated Liutie Central Hospital of Guangxi Medical University, Liuzhou, ChinaPeople’s Hospital of Rong’an County, Liuzhou, ChinaDepartments of Clinical Laboratory, Key Laboratory of medical molecular diagnostics of Liuzhou, Key Laboratory for nucleic acid molecular diagnosis and application of Guangxi health and wellness Commission, Affiliated Liutie Central Hospital of Guangxi Medical University, Liuzhou, ChinaDepartments of Clinical Laboratory, Key Laboratory of medical molecular diagnostics of Liuzhou, Key Laboratory for nucleic acid molecular diagnosis and application of Guangxi health and wellness Commission, Affiliated Liutie Central Hospital of Guangxi Medical University, Liuzhou, ChinaDepartments of Clinical Laboratory, Key Laboratory of medical molecular diagnostics of Liuzhou, Key Laboratory for nucleic acid molecular diagnosis and application of Guangxi health and wellness Commission, Affiliated Liutie Central Hospital of Guangxi Medical University, Liuzhou, ChinaPeople’s Hospital of Rong’an County, Liuzhou, ChinaDepartments of Clinical Laboratory, Key Laboratory of medical molecular diagnostics of Liuzhou, Key Laboratory for nucleic acid molecular diagnosis and application of Guangxi health and wellness Commission, Affiliated Liutie Central Hospital of Guangxi Medical University, Liuzhou, ChinaPeople’s Hospital of Rong’an County, Liuzhou, ChinaDepartments of Clinical Laboratory, Key Laboratory of medical molecular diagnostics of Liuzhou, Key Laboratory for nucleic acid molecular diagnosis and application of Guangxi health and wellness Commission, Affiliated Liutie Central Hospital of Guangxi Medical University, Liuzhou, ChinaDepartments of Clinical Laboratory, Key Laboratory of medical molecular diagnostics of Liuzhou, Key Laboratory for nucleic acid molecular diagnosis and application of Guangxi health and wellness Commission, Affiliated Liutie Central Hospital of Guangxi Medical University, Liuzhou, ChinaBackground: Recent studies highlight the carcinogenesis role of SHC-adaptor protein 1 (SHC1) in cancer initiation, development, and progression. However, its aberrant expression, diagnostic and prognostic value remain unknown in a variety of tumors.Methods: The SHC1 expression profiles were analyzed using GTEx database, TCGA database, Oncomine and CPTAC database. The survival analysis was conducted using GEPIA2, Kaplan-Meier Plotter, UALCAN, and PrognoScan. The diagnostic values of SHC1 were calculated with the “pROC” package in R software. The genetic alteration of SHC1 and mutations were analyzed using cBioPortal. TIMER2 was employed to estimate the correlations between SHC1 expression and tumor-infiltrating immune cells in the TCGA cohort. Enrichment analysis of SHC1 was conducted using the R package “clusterProfiler.”Results: SHC1 was ubiquitously highly expressed and closely associated with worse prognosis of multiple major cancer types (all p < 0.05). Further, SHC1 gene mutations were strongly linked to poor OS and DFS in SKCM (all p < 0.05). An enhanced phosphorylation level of SHC1 at the S139 site was observed in clear cell RCC. Additionally, the results revealed SHC1 expression was strongly linked to TMB, MMRs, MSI, TAMs, DNA methylation, m6A RNA methylation, tumor-associated immune infiltration, and immune checkpoints in multiple cancers (all p < 0.05). In addition, the results of the ROC analysis indicated the SHC1 exhibited strong diagnostic capability for KICH (AUC = 0.92), LIHC (AUC = 0.95), and PAAD (AUC = 0.95). Finally, enrichment analysis indicated that SHC1 may potentially involve in the regulation of numerous signaling pathways in cancer metabolism and protein phosphorylation-related functions.Conclusions: These findings highlight that SHC1 plays an important role in the tumor immune microenvironment, and SHC1 has been identified to have prognostic and diagnostic value in multiple cancers. Thus, SHC1 is a potential target for cancer immunotherapy and effective prognostic and diagnostic biomarker.https://www.frontiersin.org/articles/10.3389/fgene.2022.817118/fullSHC1pan-cancertumor immunityTCGAbiomarkerprognosis |
| spellingShingle | Jianlin Chen Gan Gao Limin Li Junping Ding Xianhua Chen Jianfei Lei Haihua Long Lihua Wu Xin Long Lian He Yongqi Shen Jinzhong Yang Yonggang Lu Yifan Sun Pan-Cancer Study of SHC-Adaptor Protein 1 (SHC1) as a Diagnostic, Prognostic and Immunological Biomarker in Human Cancer Frontiers in Genetics SHC1 pan-cancer tumor immunity TCGA biomarker prognosis |
| title | Pan-Cancer Study of SHC-Adaptor Protein 1 (SHC1) as a Diagnostic, Prognostic and Immunological Biomarker in Human Cancer |
| title_full | Pan-Cancer Study of SHC-Adaptor Protein 1 (SHC1) as a Diagnostic, Prognostic and Immunological Biomarker in Human Cancer |
| title_fullStr | Pan-Cancer Study of SHC-Adaptor Protein 1 (SHC1) as a Diagnostic, Prognostic and Immunological Biomarker in Human Cancer |
| title_full_unstemmed | Pan-Cancer Study of SHC-Adaptor Protein 1 (SHC1) as a Diagnostic, Prognostic and Immunological Biomarker in Human Cancer |
| title_short | Pan-Cancer Study of SHC-Adaptor Protein 1 (SHC1) as a Diagnostic, Prognostic and Immunological Biomarker in Human Cancer |
| title_sort | pan cancer study of shc adaptor protein 1 shc1 as a diagnostic prognostic and immunological biomarker in human cancer |
| topic | SHC1 pan-cancer tumor immunity TCGA biomarker prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fgene.2022.817118/full |
| work_keys_str_mv | AT jianlinchen pancancerstudyofshcadaptorprotein1shc1asadiagnosticprognosticandimmunologicalbiomarkerinhumancancer AT gangao pancancerstudyofshcadaptorprotein1shc1asadiagnosticprognosticandimmunologicalbiomarkerinhumancancer AT liminli pancancerstudyofshcadaptorprotein1shc1asadiagnosticprognosticandimmunologicalbiomarkerinhumancancer AT junpingding pancancerstudyofshcadaptorprotein1shc1asadiagnosticprognosticandimmunologicalbiomarkerinhumancancer AT xianhuachen pancancerstudyofshcadaptorprotein1shc1asadiagnosticprognosticandimmunologicalbiomarkerinhumancancer AT jianfeilei pancancerstudyofshcadaptorprotein1shc1asadiagnosticprognosticandimmunologicalbiomarkerinhumancancer AT haihualong pancancerstudyofshcadaptorprotein1shc1asadiagnosticprognosticandimmunologicalbiomarkerinhumancancer AT lihuawu pancancerstudyofshcadaptorprotein1shc1asadiagnosticprognosticandimmunologicalbiomarkerinhumancancer AT xinlong pancancerstudyofshcadaptorprotein1shc1asadiagnosticprognosticandimmunologicalbiomarkerinhumancancer AT lianhe pancancerstudyofshcadaptorprotein1shc1asadiagnosticprognosticandimmunologicalbiomarkerinhumancancer AT yongqishen pancancerstudyofshcadaptorprotein1shc1asadiagnosticprognosticandimmunologicalbiomarkerinhumancancer AT jinzhongyang pancancerstudyofshcadaptorprotein1shc1asadiagnosticprognosticandimmunologicalbiomarkerinhumancancer AT yongganglu pancancerstudyofshcadaptorprotein1shc1asadiagnosticprognosticandimmunologicalbiomarkerinhumancancer AT yifansun pancancerstudyofshcadaptorprotein1shc1asadiagnosticprognosticandimmunologicalbiomarkerinhumancancer |